ArticleOphthalmology2016
Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
Article in Ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04500574 (Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- A Systematic Review of Potential Therapeutic Use of Lycium Barbarum Polysaccharides in Disease.BioMed research international · 2019Pooled it
- Besifloxacin-eluting contact lens with sustained drug delivery and enhanced bioavailability.International journal of pharmaceutics: X · 2026Article
- Overcoming Antimicrobial Resistance in Bacterial Keratitis With an Antibiotic-Eluting Contact Lens.Investigative ophthalmology & visual science · 2025Article
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Wearable health devices for pediatric ophthalmology.NPJ digital medicine · 2025Review
- From Vision Correction to Drug Delivery: Unraveling the Potential of Therapeutic Contact Lens.Current drug delivery · 2025Review
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.Bioengineering (Basel, Switzerland) · 2024Review
- Drug Delivery Systems for Glaucoma: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Sustained Delivery of Olopatadine from Vitamin-E Loaded Contact Lenses.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024Article
- Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases.Drug delivery · 2023Review
- Inkjet drug printing onto contact lenses: Deposition optimisation and non-invasive dose verification.International journal of pharmaceutics: X · 2023Article
- Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma, review and update.Journal of nanobiotechnology · 2023Review
- Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies.Journal of clinical medicine · 2023Review
- Biomaterial Drug Delivery Systems for Prominent Ocular Diseases.Pharmaceutics · 2023Review
- Biopolymeric Coatings for Local Release of Therapeutics from Biomedical Implants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to Treat Acanthamoeba Keratitis.Pharmaceutics · 2022Article
- Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.Annals of medicine · 2022Article
- Glaucoma Treatment and Hydrogel: Current Insights and State of the Art.Gels (Basel, Switzerland) · 2022Review
- Targeting Ocular Drug Delivery: An Examination of Local Anatomy and Current Approaches.Bioengineering (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTo assess the ability of latanoprost-eluting contact lenses to lower the intraocular pressure (IOP) of glaucomatous eyes of cynomolgus monkeys.
designPreclinical efficacy study of 3 treatment arms in a crossover design.
participantsFemale cynomolgus monkeys with glaucoma induced in 1 eye by repeated argon laser trabeculoplasty.
methodsLatanoprost-eluting low-dose contact lenses (CLLO) and high-dose contact lenses (CLHI) were produced by encapsulating a thin latanoprost-polymer film within the periphery of a methafilcon hydrogel, which was lathed into a contact lens. We assessed the IOP-lowering effect of CLLO, CLHI, or daily latanoprost ophthalmic solution in the same monkeys. Each monkey consecutively received 1 week of continuous-wear CLLO, 3 weeks without treatment, 5 days of latanoprost drops, 3 weeks without treatment, and 1 week of continuous-wear CLHI. On 2 consecutive days before initiation of each study arm, the IOP was measured hourly over 7 consecutive hours to establish the baseline IOP. Two-tailed Student t tests and repeated-measures analysis of variance were used for statistical analysis.
main outcome measuresIntraocular pressure.
resultsLatanoprost ophthalmic solution resulted in IOP reduction of 5.4±1.0 mmHg on day 3 and peak IOP reduction of 6.6±1.3 mmHg on day 5. The CLLO reduced IOP by 6.3±1.0, 6.7±0.3, and 6.7±0.3 mmHg on days 3, 5, and 8, respectively. The CLHI lowered IOP by 10.5±1.4, 11.1±4.0, and 10.0±2.5 mmHg on days 3, 5, and 8, respectively. For the CLLO and CLHI, the IOP was statistically significantly reduced compared with the untreated baseline at most time points measured. The CLHI demonstrated greater IOP reduction than latanoprost ophthalmic solution on day 3 (P = 0.001) and day 5 (P = 0.015), and at several time points on day 8 (P < 0.05).
conclusionsSustained delivery of latanoprost by contact lenses is at least as effective as delivery with daily latanoprost ophthalmic solution. More research is needed to determine the optimal continuous-release dose that would be well tolerated and maximally effective. Contact lens drug delivery may become an option for the treatment of glaucoma and a platform for ocular drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.